| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Cichoric acid targets HIV-1 integrase, inhibiting viral replication. It also induces reactive oxygen species (ROS) generation. The compound's antidiabetic effects are mediated through increased glucose uptake, improved insulin resistance, and attenuation of inflammation. Its antioxidant and anti-inflammatory effects are attributed to its phenolic structure, which can scavenge free radicals and modulate inflammatory signaling pathways. Cichoric acid may also inhibit hyaluronidase and protect collagen from free radical degradation.
|
|---|---|
| ln Vitro |
Cell viability decreases in response to varying doses and times of exposure to bichopric acid (10–200 μM) [1]. Through the caspase-3 route, chicoric acid (100 μM; 48 h) is induced by chicoric acid (100 μM; 48 h) to lower the protein level of p-Akt [1]. In a dosed way, chimerric acid (25, 50, or 100 μM) greatly enhanced nutritional dosage for 24 hours. , and chicoric acid improved insulin-induced supplementing to 57.7% of HepG2 cells (100 nM; 30 minutes) [2]. In HepG2 cells, chichoric acid (100 μM; 24 hours) effectively activated PI3K/Akt, restoring ischemia signaling. The viability of HepG2 cells was unaffected by chichoric acid at 100 μM [2].
In vitro studies have demonstrated that cichoric acid is a potent inhibitor of HIV-1 integrase, inhibiting viral replication in tissues. The compound exhibits antioxidant properties by neutralizing harmful free radicals and reducing oxidative stress. It also shows anti-inflammatory effects and may protect collagen from degradation. Cichoric acid's ability to induce ROS generation suggests that it may have additional biological activities beyond its antioxidant effects. However, detailed in vitro potency data (e.g., IC₅₀ values) are limited in the published literature. |
| ln Vivo |
Streptozotocin (STZ; 5 0 mg/kg; intraperitoneally) is used as a result of the inhibition of the pancreatic cell lateral wall of the diabetic renal pelvis and modulation of islet function caused by choric acid (60 mg/kg/day; 4 weeks with drinking water).
In vivo, cichoric acid has demonstrated antidiabetic properties. At 60 mg/kg/day in drinking water for 4 weeks, it inhibits pancreatic apoptosis and regulates islet function in diabetic mice. At 50 mg/kg administered intraperitoneally for 5 days, it increases insulin production and secretion in C57BL/6J mice. The compound also improves insulin resistance and attenuates glucosamine-induced inflammation. These findings suggest that cichoric acid has potential therapeutic applications in diabetes and inflammatory diseases. |
| Enzyme Assay |
In vitro non-cell enzyme assays for cichoric acid typically involve measuring HIV-1 integrase inhibition using purified integrase enzyme and a DNA substrate. The compound is incubated with integrase and substrate, and enzyme activity is measured by detecting the integration product using gel electrophoresis or fluorescence-based methods. Antioxidant activity is measured using DPPH, ABTS, or FRAP assays. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cell viability assay[1]
Cell Types: 3T3-L1 preadipocyte Tested Concentrations: 10-200 μM Incubation Duration: 24, 48 GLUT2 translocation injury[2]. and 72 hrs (hours) Experimental Results: 10-50μM for 24 hrs (hours) had no effect on the viability of 3T3-L1 preadipocytes, but 100μM and 200μM Dramatically diminished cell viability. Apoptosis analysis [1] Cell Types: 3T3-L1 preadipocyte Tested Concentrations: 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: DAPI and AO/EB staining demonstrated typical cell shrinkage, chromatin condensation, and increased cell membrane permeability. characteristics of apoptosis. Western Blot Analysis[1] Cell Types: 3T3-L1 Preadipocytes Tested Concentrations: 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: p-Akt protein levels diminished in a dose- and time-dependent manner. Total Akt protein levels are not affected In vitro cell-based assays for cichoric acid use HIV-infected cell lines to evaluate antiviral activity, measuring viral replication by p24 antigen ELISA or RT-PCR. For antidiabetic studies, adipocytes or muscle cells are treated with cichoric acid, and glucose uptake is measured using radiolabeled glucose or fluorescent glucose analogues. Inflammatory cytokine production is measured by ELISA in LPS-stimulated macrophages. Apoptosis is assessed by Annexin V/PI staining and flow cytometry. |
| Animal Protocol |
Animal/Disease Models: C57BL/6J mice The generation and death of C57BL/6J mice with STZ (50 mg/kg; ip; for 5 days) [3]. kg
Route of Administration: drinking water; daily; continued for 4 weeks Experimental Results: Inhibited pancreatic cell apoptosis and adjusted pancreatic islet function in diabetic mice, resulting in increased insulin production and secretion. Regulates mitochondrial biogenesis, glycogen synthesis and suppresses inflammation by activating antioxidant responses. From the 7th week onwards, there was a significant weight gain. In vivo animal studies for cichoric acid employ rodent models of diabetes, such as streptozotocin-induced diabetic mice or high-fat diet-induced obese mice. The compound is administered orally in drinking water at 60 mg/kg/day for 4 weeks or intraperitoneally at 50 mg/kg for 5 days. Parameters assessed include blood glucose levels, insulin levels, glucose tolerance (OGTT), pancreatic islet histology, apoptosis markers in pancreatic tissues, and inflammatory cytokine levels. |
| ADME/Pharmacokinetics |
Cichoric acid has a molecular weight of 474.37 g/mol and a molecular formula of C₂₂H₁₈O₁₂. It is also known as chicoric acid or dicaffeoyltartaric acid. The compound is a water-soluble phenolic acid and is orally active. It should be stored at appropriate conditions as recommended by the manufacturer. Detailed pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
Cichoric acid is generally considered to have low toxicity based on its natural occurrence in chicory and other plants. In animal studies at doses of 60 mg/kg/day, no significant toxicity has been reported. The compound is classified as a research reagent and is not intended for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicological studies have not been performed.
|
| References |
|
| Additional Infomation |
Chicoric acid is an oxygen-containing organic compound. It has the effects of inhibiting HIV-1 integrase and delaying aging. Its function is related to tetracarboxylic acids. Chicoric acid has been reported to be found in tea (Camellia sinensis), Coptis chinensis (Hydrastis canadensis), and several other organisms with relevant data.
Cichoric acid is a water-soluble phenolic acid compound extracted from chicory (Cichorium intybus). It is also known as chicoric acid or dicaffeoyltartaric acid. The compound is a potent HIV-1 integrase inhibitor with antiviral activity. It has antidiabetic properties and antioxidant, anti-inflammatory effects. Cichoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C22H18O12
|
|---|---|
| Molecular Weight |
474.3711
|
| Exact Mass |
474.079
|
| CAS # |
6537-80-0
|
| Related CAS # |
L-Chicoric Acid;70831-56-0
|
| PubChem CID |
5281764
|
| Appearance |
White to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
785.0±60.0 °C at 760 mmHg
|
| Flash Point |
272.9±26.4 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.726
|
| LogP |
3.81
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
34
|
| Complexity |
740
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC(=C(C=C1/C=C/C(=O)O[C@@H](C(=O)O)[C@@H](OC(=O)/C=C/C2=CC(=C(C=C2)O)O)C(=O)O)O)O
|
| InChi Key |
YDDGKXBLOXEEMN-IABMMNSOSA-N
|
| InChi Code |
InChI=1S/C22H18O12/c23-13-5-1-11(9-15(13)25)3-7-17(27)33-19(21(29)30)20(22(31)32)34-18(28)8-4-12-2-6-14(24)16(26)10-12/h1-10,19-20,23-26H,(H,29,30)(H,31,32)/b7-3+,8-4+/t19-,20-/m1/s1
|
| Chemical Name |
(2R,3R)-2,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~210.81 mM)
DMSO : ~1 mg/mL (~2.11 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (105.40 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1081 mL | 10.5403 mL | 21.0806 mL | |
| 5 mM | 0.4216 mL | 2.1081 mL | 4.2161 mL | |
| 10 mM | 0.2108 mL | 1.0540 mL | 2.1081 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
